AlzeCure Pharma Stock Pitch

Redeye's investment thesis suggests that AlzeCure is undervalued, as the market overlooks the potential and quality of its neurology projects. The company's research and development, led by former AstraZeneca scientists, is considered high-quality and is validated by financial support from the EIC. Near-term catalysts include potential licensing or partnership deals. Redeye's DCF valuation model suggests a base case of SEK 6 per share.